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Association of IL1RAP-related 
genetic variation with cerebrospinal 
fluid concentration of Alzheimer-
associated tau protein
Anna Zettergren1, Kina Höglund  2,3, silke Kern1, Valgeir thorvaldsson4, Msc Johan skoog1,4, 
oskar Hansson5, Niels Andreasen6, Nenad Bogdanovic7, Kaj Blennow2,3, Ingmar skoog1 & 
Henrik Zetterberg2,3,8,9
A possible involvement of the gene IL1RAP (interleukin-1 receptor-associated protein) in the 
pathogenesis of Alzheimer’s disease (AD) has been suggested in GWASs of cerebrospinal fluid (CSF) tau 
levels and longitudinal change in brain amyloid burden. The aim of this study was to examine previously 
implicated genetic markers in and near IL1RAP in relation to AD risk, CSF tau and Aβ biomarkers, as well 
as cognitive decline, in a case (AD)-control study and an age homogenous population-based cohort. 
Genotyping of IL1RAP-related single nucleotide polymorphisms (SNPs), selected based on previous 
GWAS results, was performed. 3446 individuals (1154 AD cases and 2292 controls) were included in 
the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker 
analyses, and 861 individuals in the analyses of cognitive decline. We found no relation between 
IL1RAP-related SNPs and AD risk. However, CSF total-tau and phospho-tau were associated with the 
SNP rs9877502 (p = 6 × 10−3 and p = 5 × 10−4). Further, nominal associations (p = 0.03–0.05) were 
found between three other SNPs and CSF biomarker levels, or levels of cognitive performance and 
decline in a sub-sample from the general population. These results support previous studies suggesting 
an association of IL1RAP with disease intensity of AD.
Low-grade activation of the immune system has for a long time been implicated in Alzheimer’s disease (AD) 
pathogenesis and accumulating evidence has demonstrated the involvement of microglia in this process1. 
Cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and transform-
ing growth factor beta (TGFβ), are involved in the regulation of microglial function and may react or contribute 
to AD-associated pathologies and/or mediate neurotoxicity2.
Several genome-wide association studies (GWASs) have indicated that single nucleotide polymorphisms 
(SNPs) in and near IL1RAP (interleukin-1 receptor-associated protein) may be associated with AD. One of these 
studies that primarily focused on longitudinal change in brain amyloid burden found associations with SNPs 
located in IL1RAP3. In addition, sub-analyses showed associations between the most significant IL1RAP SNP and 
progression from MCI to AD, longitudinal temporal cortex atrophy on MRI, cognitive decline, and microglial 
activity on PET. In a study of cerebrospinal fluid (CSF) tau levels, the most significant findings (APOE taken 
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aside) were intergenic SNPs located close to IL1RAP4. Gene expression analyses of candidate genes (GEMC1, 
OSTN, and IL1RAP) located within the same region (Chr:3q28) as these intergenic SNPs showed association 
between the most significant SNP (rs9877502) and IL1RAP expression, as well as between IL1RAP expression 
and case-control status, while no such associations could be seen with the other genes. Further, rs9877502 was 
associated with AD risk, tangle pathology and cognitive decline. Moreover, the association of this SNP with CSF 
tau concentration has been replicated in a recently performed large study on AD endophenotypes5.
IL1RAP is highly expressed in the brain6 and encodes a component of the IL-1 pro-inflammatory signaling 
pathway7, which is activated through binding of IL1RAP to the IL-1/IL-1 receptor complex8. Investigations of 
AD mouse models have shown that overexpression of IL-1 leads to increased activation of microglia in response 
to Aβ9,10. Further, other genes related to the IL-1 pathway (i.e. IL-1A, IL-1B, and IL-1 receptor antagonist 
(VNTR)) have been the focus of several previous genetic association studies, but the results have been somewhat 
inconsistent11–15.
The aim of this study was to examine the association of previously implicated genetic markers in and near 
IL1RAP in relation to AD risk, CSF tau and Aβ biomarkers, as well as cognitive decline over time, in a case 
(AD)-control study and an age homogenous representative population-based cohort.
Materials and Methods
Participants. AD cases included in this study originate from the Swedish cities Stockholm, Gothenburg, 
Malmö, Linköping, and Piteå16, and were either collected in memory clinics or as a part of two popula-
tion-based epidemiological studies in Gothenburg; the Prospective Population Study of Women (PPSW) and 
the Gothenburg Birth Cohort Studies (H70, H85 and 95+), described in detail previously17–20. Controls originate 
from Gothenburg (the population-based epidemiological studies described above) and Malmö. The majority of 
the controls recruited in Malmö belongs to the BioFINDER study, described in detail previously21,22, and were 
originally included in the population-based European Prospective Investigation of Cancer and Nutrition (EPIC) 
cohort23. All control samples were clinically investigated and free from dementia. Possible controls with an MMSE 
below 28 were excluded from the case/control analyses. Characteristics of the study sample are described in 
Table 1.
The study was approved by the Regional Ethical Review Boards in Gothenburg, Lund, Umeå, and Linköping, 
Sweden, and the tenets of the Declaration of Helsinki were followed. Informed consent was obtained from all 
participants and/or their relatives in cases of dementia.
Diagnoses and measures of cognition. AD diagnosis was based on National Institute of Neurological 
and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders (NINCDS-ADRA) crite-
ria24. Mini-Mental State Examination (MMSE) was performed according to Folstein et al.25. Additional measures 
of cognition were derived from a sub-sample of the Gothenburg H70 Birth Cohort Studies, consisting of 866 indi-
viduals, all born in 1930, and repeatedly examined at age 70, 75, and 79. A global cognitive index in the form of a 
latent variable was derived by structural equation modeling26 using the following tests: Figure Logic (reasoning), 
Figure Identification (perceptual and motor speed), Synonyms (verbal ability)27, Block Design (spatial ability), 
Digit Span Forward/Backward (short-term and working memory), Digit Symbol (perceptual and motor speed)28, 
Thurstone’s Picture Memory recognition memory)29, Supra-Span Memory (list learning recall; BUS II)30, and 
Memory in Reality (object recall)31.
Genotyping. Genotyping of single nucleotide polymorphisms (SNPs) in or near IL1RAP was performed 
using the KASPar PCR SNP genotyping system (LGC Genomics, Hoddesdon, Herts, UK). The selection of SNPs 
(rs3773976, rs12053868, rs3773970, rs4687151, rs147346019 and rs9877502) was based on findings reported in 
previous GWASs (SNPs reported among these findings, but in high LD (r2 > 0.8) with the SNPs above, were not 
included in this study)3,4. One of the selected SNPs (rs147346019) was not genotyped due to unsuccessful design 
Sample for case/control analysis
AD (n = 1154) Controls (n = 2292)
Women, n (%) 763 (66.1) 1359 (59.3)
Men, n (%) 391 (33.9) 933 (40.7)
Age at examination, mean (SD) 77.4 (8.0) 75.4 (7.1)
MMSE, mean (SD) 19.6 (6.6) 29.2 (0.8)
Sub-sample with data on CSF-biomarkers
AD (n = 653) Non-dem (n = 747)
Women, n (%) 400 (61.3) 402 (53.8)
Men, n (%) 253 (38.7) 345 (46.2)
Age at examination, mean (SD) 75.5 (6.9) 73.2 (5.6)
MMSE, mean (SD) 20.7 (5.5) 28.9 (1.5)
Abeta42 (pg/ml), mean (SD) 463 (131) 697 (214)
t-tau (pg/ml), mean (SD) 682 (367) 353 (167)
p-tau (pg/ml), mean (SD) 83 (36) 55 (20)
Table 1. Sample Characteristics.
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of the KASP-assay. The success rate for the genotyped SNPs was >95% and all SNPs were in Hardy-Weinberg 
equilibrium.
Measures of CSF-biomarkers. CSF total tau (t-tau), phosphorylated tau 181 (p-tau) and amyloid β 42 
(Aβ42) concentrations were measured using INNOTEST ELISA32–34, ELISA-normalized AlzBio3 (Fujirebio, 
Ghent, Belgium), or INNOTEST-normalized EUROIMMUN (only t-tau).
Statistics. Relations between AD diagnosis and IL1RAP SNPs were investigated by comparing cases and 
controls in logistic regression models adjusted for sex and age at examination. CSF t-tau, p-tau and Aβ42 concen-
trations were log-transformed to approximate normal distribution. Possible associations with IL1RAP SNPs were 
then investigated using linear regressions adjusted for sex and age at examination. In addition, the analyses were 
repeated after inclusion of APOE ɛ4 status in the regression models. The p-values generated in the CSF biomarker 
analyses were corrected for multiple testing using an FDR-based approach and shown as q-values.
Relations between IL1RAP SNPs and level and change in cognitive function were investigated using 
second-order latent growth curve models35 within structural equation modelling36. The latent outcome variable 
(i.e., global cognition) was derived from the variance/covariance matrix structure of the cognitive test specified 
above at ages 70, 75, and 79. Factor loadings of the slope component were specified as 0, 5, and 9, and thereby 
reflecting chronological age centered at baseline i.e., age 70 (note that this is an age-homogenous sample). IL1RAP 
SNPs, sex, and subsequent dementia diagnosis were all included as main effect into the model, and IL1RAP SNPs 
by age was included as two-level interaction. Individuals with dementia at baseline (n = 5) were excluded from 
the analyses. The analyses were repeated after inclusion of APOE ɛ4 status as main effect, IL1RAP SNPs by APOE 
ɛ4 two-level interaction, and IL1RAP SNPs by APOE ɛ4 by age three-level interaction.
Results
None of the investigated SNPs were associated with AD risk (Supplementary Table 1). However, analyses of the 
total sample with data on CSF biomarkers, showed that the SNP rs9877502 was associated with t-tau and p-tau 
levels; carriers of the A-allele had higher tau-levels (Table 2). In the additive model (genotypes coded 0, 1, 2), 
adjusted for sex and age at examination, only p-tau was significant (Beta = 0.055 (CI:0.022–0.088), p = 1 × 10−3), 
but in the dominant model (comparing GG-carriers with AA + AG carriers), adjusted for sex and age at exam-
ination, both t-tau and p-tau were significant (Beta = 0.084 (CI:0.023–0.144), p = 6 × 10−3, and Beta = 0.084 
(CI:0.037–0.131), p = 5 × 10−4, respectively). The associations with p-tau levels remained significant after cor-
rection for multiple testing (see q-values in Table 2).When the sample was stratified by AD diagnosis, significant 
associations, and a stronger effect size (Beta), for t-tau, were seen in the group without dementia (additive model: 
Beta = 0.083 (CI:0.038–0.128), p = 3 × 10−4; dominant model: Beta = 0.12 (CI:0.054–0.182), p = 3 × 10−4), while 
significant associations, of similar effect sizes, for p-tau were seen among both dementia free individuals (additive 
model: Beta = 0.067 (CI:0.033–0.102), p = 1 × 10−4; dominant model: Beta = 0.10 (CI:0.052–0.150), p = 6 × 10−5) 
and AD cases (additive model: Beta = 0.054 (CI:0.003–0.106), p = 0.04; dominant model: Beta = 0.086 (CI:0.012-
0.159), p = 0.02. Among dementia free individuals both the associations with t-tau and p-tau remained significant 
after correction for multiple testing. In addition, nominally significant associations (p = 0.03–0.05), not holding 
after correction for multiple testing, were found between rs3773970 and Aβ42 levels, as well as between rs4687151 
and tau levels, in individuals with AD, and between rs12053868 and tau levels, as well as between rs4687151 and 
both Aβ42 and tau levels, in dementia free individuals (see Table 2). Results similar to those presented in Table 2 
were found after including APOE ɛ4 status as a covariate in the regression models.
Analyses of cognitive decline in a sub-sample of individuals from the general population showed no associ-
ations when only IL1RAP SNPs were included in the growth curve models. However, after including APOE ɛ4 
status, a nominally significant interaction between rs3773976 and APOE ɛ4 status was seen, where carriership of 
the rare allele (i.e., GT and GG) was related to lower cognitive performance among APOE ɛ4 carriers (d = 0.59, 
p = 0.04) and a faster decline among non APOE ɛ4 carriers ((d = −0.12, p = 0.03); see Supplementary Table 2 and 
Supplementary Fig. 1). A similar trend (lower cognitive performance in carriers of at least one minor IL1RAP 
allele among individuals with at least one APOE ɛ4 allele) was seen for all other SNPs located in the IL1RAP gene 
(rs12053868, rs3773970, rs4687151).
Discussion
In this study, we investigated previously implicated SNPs in and near the gene IL1RAP, located at chromosome 
3, in relation to AD risk, CSF tau and Aβ biomarkers, and cognitive function. While no associations were seen 
with AD risk, we replicated a previously identified association with tau-levels, and found nominally significant 
associations with cognitive decline and level.
Previous genetic studies, primarily on CSF biomarkers and longitudinal change in brain amyloid burden, have 
reported associations between ILRAP-related SNPs and AD risk as well as progression from MCI to AD3,4. In this 
study we could not detect an association between the investigated IL1RAP SNPs and AD risk, but our sample size 
is small compared to the large case-control sample used for investigating AD risk in the study by Chruchaga and 
colleagues.
In our analyses of CSF biomarkers versus IL1RAP SNPs, the strongest associations, which remained signif-
icant after correction for multiple testing, were found between carriership of the A-allele (the minor allele) of 
SNP rs9877502 and elevated tau-levels. This finding is in line with the results in two previous GWASs4,5. Further, 
rs9877502, or highly linked SNPs at the same loci, were the only ones that were associated with AD risk, burden 
of tau pathology and cognitive decline4,5. rs9877502 is located in an intergenic region, but bioinformatic analy-
ses have shown that this SNP, as well as 33 additional SNPs in LD with rs9877502, are located in transcription 
factor-binding sites and some of the SNPs are part of a transcription factor matrix. These findings suggest that 
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p1 q1 p2 q2 n (%)
t-tau (pg/ml)
p1 q1 p2 q2 n (%)
p-tau (pg/ml)
p1 q1 p2 q2SNP mean (SD) mean (SD) mean (SD)
rs3773976
GG 13 (1.0) 667 (271) 0.31 0.44 13 (0.9) 472 (150) 0.41 0.37 13 (1.0) 63 (19) 0.15 0.15
GT 259 (19.0) 585 (231) 0.63 0.70 262 (19.0) 493 (326) 0.68 0.66 246 (19.0) 65 (29) 0.42 0.43
TT 1090 (80.0) 573 (220) 1102 (80.0) 508 (323) 1033 (80.0) 68 (32)
rs12053868
GG 9 (0.7) 742 (282) 0.19 0.32 9 (0.7) 403 (117) 0.93 0.83 9 (0.7) 62 (14) 0.81 0.81
GA 256 (18.8) 584 (222) 0.46 0.65 259 (18.8) 520 (386) 0.79 0.81 248 (19.2) 68 (36) 0.76 0.81
AA 1096 (78.5) 572 (222) 1108 (80.5) 505 (310) 1036 (80.1) 67 (30)
rs3773970
TT 13 (1.0) 636 (278) 0.85 0.73 13 (0.9) 428 (162) 0.66 0.58 13 (1.0) 62 (19) 0.98 0.98
TC 285 (20.9) 573 (224) 0.77 0.81 289 (20.9) 525 (382) 0.73 0.76 272 (21.0) 68 (36) 0.80 0.91
CC 1067 (78.2) 576 (222) 1078 (78.1) 503 (309) 1012 (78.0) 67 (30)
rs4687151
GG 55 (4.0) 585 (232) 0.88 0.80 56 (4.0) 484 (297) 0.43 0.26 53 (4.1) 67 (28) 0.53 0.49
GC 448 (32.7) 575 (224) 0.77 0.81 452 (32.7) 528 (370) 0.68 0.59 424 (32.6) 68 (34) 0.71 0.72
CC 866 (63.3) 577 (222) 876 (63.3) 496 (300) 824 (63.3) 66 (30)
rs9877502
AA 197 (14.6) 561 (224) 0.42 0.80 200 (14.7) 485 (291) 0.07 6 × 10−3 191 (14.9) 68 (30) 1 × 10−3 5 × 10−4
AG 623 (46.1) 581 (224) 0.68 0.81 630 (46.2) 535 (361) 0.26 0.06 589 (45.9) 69 (33) 0.01 7 × 10−3




p1 q1 p2 q2 n (%)
t-tau (pg/ml)
p1 q1 p2 q2 n (%)
p-tau (pg/ml)
p1 q1 p2 q2SNP mean (SD) mean (SD) mean (SD)
rs3773976
GG 6 (1.0) 467 (189) 0.20 0.14 6 (0.9) 561 (122) 0.87 0.75 6 (1.1) 66 (26) 0.77 1.00
GT 106 (16.9) 424 (144) 0.46 0.43 109 (17.0) 690 (387) 0.77 0.81 93 (16.7) 82 (31) 0.76 0.91
TT 516 (82.2) 438 (128) 528 (82.1) 679 (361) 459 (82.3) 83 (37)
rs12053868
GG 3 (0.5) 562 (257) 0.56 0.40 3 (0.5) 469 (117) 0.40 0.29 3 (0.5) 73 (17) 0.60 0.56
GA 100 (15.9) 427 (140) 0.71 0.67 103 (16.0) 746 (497) 0.68 0.63 92 (16.5) 88 (47) 0.71 0.76
AA 524 (83.6) 436 (128) 536 (83.5) 674 (337) 464 (83.0) 82 (34)
rs3773970
TT 5 (0.8) 371 (109) 0.05 0.06 5 (0.8) 566 (126) 0.27 0.20 5 (0.9) 74 (23) 0.43 0.35
TC 119 (18.9) 424 (138) 0.26 0.22 123 (19.1) 740 (473) 0.58 0.51 106 (18.9) 88 (45) 0.68 0.65
CC 505 (80.3) 438 (129) 516 (80.1) 673 (338) 450 (80.2) 82 (34)
rs4687151
GG 21 (33.5) 425 (125) 0.76 0.81 22 (34.3) 687 (347) 0.06 0.03 19 (3.4) 86 (30) 0.05 0.04
GC 192 (30.6) 436 (130) 0.76 0.81 196 (30.5) 737 (446) 0.26 0.21 168 (30.1) 88 (41) 0.26 0.21
CC 414 (66.0) 434 (130) 424 (66.0) 660 (324) 372 (66.5) 81 (34)
rs9877502
AA 85 (13.8) 441 (164) 0.59 0.22 88 (13.9) 626 (344) 0.81 0.07 79 (14.4) 85 (34) 0.04 0.02
AG 287 (46.4) 432 (125) 0.71 0.53 294 (46.4) 735 (417) 0.76 0.24 253 (46.0) 86 (38) 0.26 0.16




p1 q1 p2 q2 n (%)
t-tau (pg/ml)
p1 q1 p2 q2 n (%)
p-tau (pg/ml)
p1 q1 p2 q2SNP mean (SD) mean (SD) mean (SD)
rs3773976
GG 7 (1.0) 838 (208) 0.50 0.71 7 (1.0) 396 (134) 0.62 0.81 7 (1.0) 60 (12) 0.60 0.41
GT 153 (20.8) 697 (213) 0.71 0.81 153 (20.8) 353 (168) 0.71 0.81 153 (20.8) 54 (21) 0.71 0.67
TT 574 (78.2) 694 (214) 574 (78.2) 350 (166) 574 (78.2) 55 (20)
rs12053868
GG 6 (0.8) 832 (268) 0.97 0.75 6 (0.8) 370 (112) 0.03 0.04 6 (0.8) 56 (9) 0.45 0.54
GA 156 (21.3) 684 (206) 0.80 0.81 156 (21.3) 371 (171) 0.26 0.21 156 (21.3) 56 (20) 0.69 0.76
AA 572 (77.9) 697 (216) 572 (77.9) 348 (167) 572 (77.9) 55 (20)
rs3773970
TT 8 (1.1) 801 (211) 0.69 0.47 8 (1.1) 342 (119) 0.15 0.16 8 (1.1) 55 (12) 0.81 0.96
TC 166 (22.6) 680 (212) 0.74 0.72 166 (22.6) 365 (172) 0.42 0.44 166 (22.6) 55 (20) 0.76 0.91
CC 562 (76.4) 700 (214) 562 (76.4) 348 (166) 562 (76.4) 55 (20)
Continued
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the variants can influence the expression of genes located in the same region and gene expression analyses have 
shown that rs9877502 was significantly associated with the expression level of IL1RAP in frontal cortex. Since 
rs9877502 is an intergenic SNP, additional genes located in the same region could possibly be influenced by 
this variant. However, gene expression analyses of other genes in the region (3q28) showed no association with 
rs98775024.
In our study, we noted stronger effect sizes (based on beta) for the associations between rs9877502 and t-tau 
CSF levels among dementia free individuals than in AD cases, while the effect size for the associations with 
p-tau seemed to be similar in both groups. However, based on p- and q-values, also p-tau shows a stronger 
association in the dementia free group. Across neurodegenerative diseases, both CSF t-tau and p-tau are surpris-
ingly AD-specific37 and reflect disease intensity38. The previously suggested relationship between CSF t-tau and 
p-tau with neurodegeneration and tangle pathology, respectively, is not as clear as previously thought39. Another 
interpretation, supported by recent data from human in vivo labeling studies40, is that AD-affected neurons may 
secrete more of both t-tau and p-tau in response to Aβ exposure. Such neurons may be at increased risk of 
developing tangles and eventually die but this would be downstream of the tau dysmetabolism and release that 
the currently available static assays measure. A possible explanation to our result might be that inflammatory 
processes in the brain may represent a tissue response that either mediate or is closely associated with increased 
neuronal tau secretion. This may be easier to detect during the pre-clinical stage of AD when there is still a large 
enough number of neurons left that can react in this way. In support of this are biomarker studies demonstrating 
increased inflammation and microglial activation in the prodromal phase of AD41,42. In the GWASs by Cruchaga 
et al.4 and Deming et al.5, the associations for p-tau were similar in cases and controls, which is in line with our 
results. No stratified results for t-tau were reported in these studies.
Analyses of cognitive function in a sub-sample from the general population, showed a modest association 
with both cognitive level and decline for the SNP rs3773976. Carriers of the rare allele had poorer average cogni-
tive performance in individuals with at least one APOE ɛ4 allele, and faster cognitive decline in individuals with 
no APOE ɛ4 alleles. Similar trends, although non-significant, were found for three of the other SNPs (rs12053868, 
rs3773970, and rs4687151), all linked to rs37739976. This finding is to some extent in line with the result in the 
study by Ramanan et al.3, showing faster cognitive decline, measured as difference in verbal episodic memory 
performance, among carriers of the rare alleles of the SNP rs12053868 (r2 = 0.4 with rs37739976) in APOE ɛ4 
individuals. However, the association with decline in our study was mainly seen in non APOE ɛ4 carriers, and no 
result for cognitive level was reported in the Ramanan study. Further, the mean age of their sample was 75 years at 
baseline, and the individuals were recruited from the Alzheimer’s disease neuroimaging initiative43, the religious 
orders study44, and the rush Memory and Aging project45, thus not from the general population. This result in a 
higher proportion of AD-individuals included compared to our study.
Cruchaga and colleagues reported an association between rs9877502 and decline of global cognitive function 
(based on a composite score of 17 neuropsychiatric tests) in a sample without known dementia at recruitment4. 
This association was stronger than any other association between this SNP and AD-related phenotypes (apart 
from the CSF-markers primarily investigated). We could not detect this association in our sample, but, as already 
stated, this can be related to differences in age (mean age at enrollment was 78.5 years in their sample), testing and 
recruitment of individuals. Furthermore, our sample was smaller than the sample used in the study by Cruchaga 
et al., possibly giving rise to power issues.
The investigated SNPs located within the IL1RAP gene are all intronic and, similar to rs9877502, their possible 
functionality is not well established. However, it has been suggested, based on preliminary data, that rs12053868 is 
associated with decreased IL1RAP expression in the cortex and hippocampus3, and associations between intronic 
IL1RAP SNPs (although others than those included in the present study) and plasma-levels of soluble IL1RAP 
protein46 have been reported.
The strengths with our study are the well examined participants and the homogeneous, and relatively large, 
CSF biomarker sample. A limitation is that the analyses were done at different time points, although they were all 




p1 q1 p2 q2 n (%)
t-tau (pg/ml)
p1 q1 p2 q2 n (%)
p-tau (pg/ml)
p1 q1 p2 q2SNP mean (SD) mean (SD) mean (SD)
rs4687151
GG 34 (4.6) 684 (228) 0.07 0.05 34 (4.6) 352 (157) 0.08 0.05 34 (4.6) 56 (20) 0.55 0.59
GC 256 (34.5) 679 (222) 0.26 0.21 256 (34.5) 368 (174) 0.27 0.21 256 (34.5) 56 (20) 0.71 0.76
CC 452 (60.1) 708 (209) 452 (60.1) 343 (164) 452 (60.1) 55 (20)
rs9877502
AA 112 (15.3) 652 (222) 0.17 0.34 112 (15.3) 374 (175) 3 × 10−4 3 × 10−4 112 (15.3) 57 (21) 1 × 10−4 6 × 10−5
AG 336 (45.9) 709 (210) 0.44 0.65 336 (45.9) 360 (164) 5 × 10−3 6 × 10−3 336 (45.9) 57 (20) 3 × 10−3 2 × 10−3
GG 284 (38.8) 697 (212) 284 (38.8) 332 (166) 284 (38.8) 52 (19)
Table 2. Associations between IL1-RAP related SNPs and levels of CSF-biomarkers. p-values are based on 
linear regressions of log-transformed biomarker values, adjusted for sex and age at CSF-examination. p-values 
corrected for multiple testing, based on FDR, are shown as q-values. p1 and q1: additive model (coding: 0, 1 
or 2 copies of the minor allele). p2 and q2: dominant model where the rare homozygotes are merged with the 
heterozygotes.
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this study are small compared to previous studies reporting associations with IL1RAP-related SNPs. Therefore, 
we cannot exclude that our negative findings, in relation to these outcomes, are due to insufficient power to detect 
possible associations.
In conclusion, the main finding in our study was a replication of the association between the SNP rs9877502 
and tau levels in a large homogeneous sample with data on CSF biomarkers. The association seems to be strongest 
among individuals without dementia. In addition, nominally significant associations were found between three of 
the other investigated SNPs and CSF biomarker levels, as well as cognitive function in a sub-sample from the gen-
eral population. These results support previous studies suggesting an association of IL1RAP with disease intensity 
of AD, although further studies investigating the functionality of these variants, as well as possible biological roles 
of IL1RAP in the AD process, are needed.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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